Clinical trial
Vinorelbine With or Without Trastuzumab in Treating Women With Progressive…
NCT00103233 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00103233 |
|---|---|
| Title | Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer |
| Official title | A Randomized Study of Weekly Vinorelbine (Navelbine®) Alone or in Combination With Trastuzumab (Herceptin®) (NSC-688097) for Patients With HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, vinorelbine tartrate |
| Start date | Dec 1, 2004 |
| Completion | Apr 1, 2006 |
| First posted | Feb 8, 2005 |
| Last update posted | Jun 24, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: